Previous 10 | Next 10 |
January 13, 2020 Palm Beach, FL –January 13, 2020 – Reports say that the global drug delivery across brain barrier market size is expected to reach USD $4.6 billion by 2026, according to a new report by Grand View Research, Inc. registering a CAGR of 30.2% over the f...
HOUSTON , Jan. 13, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biotechnology company specializing in the development of novel treatments for brain tumors, today announced it has entered into a licensing agreement with MD Anderson to in...
December 17, 2019 Palm Beach, FL –December 17, 2019 – The success rate for cancer therapies has been limited due to a combination of factors, such as the treatment/drug’s lack of penetration through the blood brain barrier. Reports say that the global drug d...
HOUSTON , Dec. 17, 2019 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biotechnology company specializing in the development of novel treatments for brain tumors, today announced the completed good manufacturing practice (GMP) reprocessing o...
December 11, 2019 Palm Beach, FL –December 11, 2019 – According to various industry and market publications, pharmaceutical companies spend, on average, 17% of revenues on R&D, making it one of the biggest spenders in this area. Outside of the semiconductor industry,...
December 11, 2019 Palm Beach, FL –December 11, 2019 – For the last half century, if not more, doctors have been working to learn more about brain tumors, ways to prevent them, how to best treat them, and how to provide the best care to people diagnosed with a brain tumor...
HOUSTON , Dec. 11, 2019 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biotechnology company specializing in the development of novel treatments for brain tumors, announced that its partner, WPD Pharmaceuticals ("WPD"), a Polish corpora...
December 10, 2019 Palm Beach, FL –December 10, 2019 – There are so many paths that R&D is taking in the ongoing fight against cancer. New drugs, new therapies and new techniques are developed to help researchers and practitioners across all cancer sub-markets. One su...
December 10, 2019 Palm Beach, FL –December 10, 2019 – Much R&D from companies and investors has been pouring into the targeted drug therapies markets, enabling pharma companies and other industry researchers to find better and more effective ways to combat cancer in ...
HOUSTON , Dec. 10, 2019 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biotechnology company specializing in the development of novel treatments for brain tumors, received positive feedback from the U.S. Food and Drug Administration (FDA) for its...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
18.56%Change Percent:
CNS Pharmaceuticals Inc. Company Name:
CNSP Stock Symbol:
NASDAQ Market:
CNS Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 7.0% to $103.73 on volume of 461,121,707 shares PROSHARES TRUST (SQQQ) rose 4.2% to $9.43 on volume of 197,353,222 shares Agape ATP Corporation (ATPC) rose 54.3% to $0.135 on volume of 196,014,250 shares ...
A look at the top 10 most actives in the United States Agape ATP Corporation (ATPC) rose 148.2% to $0.2172 on volume of 69,599,062 shares Imunon Inc. (IMNN) rose 154.6% to $3.03 on volume of 68,427,736 shares Jet.AI Inc. (JTAI) rose 27.2% to $0.380102 on volume of 41,454,602 shares SoFi T...
Strategic in-license from Cortice Bioscience is highly synergistic with the ongoing potentially pivotal Berubicin program and demonstrates further commitment to changing the treatment paradigm in GBM Drug candidate, TPI 287, awarded Orphan designation and studied in over 350 patients to date...